Related references
Note: Only part of the references are listed.Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial)
Robert D. McBane et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2010)
Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study
A. G. Tabak et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Matthew P. Gilbert et al.
AMERICAN JOURNAL OF MEDICINE (2009)
The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction
Bernard R. Chaitman et al.
CIRCULATION (2009)
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
Giuseppe Derosa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes The LANCET Randomized Trial
Aruna D. Pradhan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of plasminogen activator inhibitor-1 - Its mechanism and effectiveness on coagulation and fibrosis
Yuko Izuhara et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents
K. M. Katsaros et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
Maria Mori Brooks et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1
YB Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1)
DJ Schneider et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis
BE Sobel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1α, tumor necrosis factor-α, transforming growth factor-β and oncostatin M in human cardiac myocytes
K Macfelda et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2002)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
YT Kruszynska et al.
DIABETES (2000)
Share Paper
